Compare METC & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | METC | IMCR |
|---|---|---|
| Founded | 2015 | 2008 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Coal Mining | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.7B |
| IPO Year | 2017 | 2021 |
| Metric | METC | IMCR |
|---|---|---|
| Price | $15.54 | $36.52 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 9 |
| Target Price | $38.69 | ★ $67.00 |
| AVG Volume (30 Days) | ★ 3.0M | 338.1K |
| Earning Date | 10-27-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $579,503,000.00 | $379,590,000.00 |
| Revenue This Year | N/A | $32.31 |
| Revenue Next Year | $21.27 | $10.50 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 28.11 |
| 52 Week Low | $6.30 | $23.15 |
| 52 Week High | $57.80 | $40.72 |
| Indicator | METC | IMCR |
|---|---|---|
| Relative Strength Index (RSI) | 33.13 | 49.05 |
| Support Level | $15.31 | $35.35 |
| Resistance Level | $16.94 | $40.71 |
| Average True Range (ATR) | 1.32 | 1.82 |
| MACD | 0.58 | -0.45 |
| Stochastic Oscillator | 16.78 | 22.55 |
Ramaco Resources Inc is a United States-based company that operates as a pure-play metallurgical coal company with operations in southern West Virginia and southwestern Virginia. Its portfolio includes high-quality metallurgical coal reserves & resources, with a focus on properties such as Elk Creek, Berwind, Knox Creek, and Maben. These properties are strategically located to serve North American blast furnace steel mills and coke plants, as well as international metallurgical coal consumers. Additionally, the company controls mineral deposits in Sheridan, Wyoming, exploring potential opportunities in rare earth elements and coal-to-carbon-based products. Operations are concentrated in the Appalachian basin, with active mines at Elk Creek, Berwind, Knox Creek, and Maben mining complexes.
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.